Rather than using the median as a cut off point above which G250/CA9, PRAME, RHAMM and MGEA6 expression were shown to be associated with improved prognosis (Greiner et al. 2006), there has been a recent suggestion that a group of “distinctly” high expressing AML patients could be identified by real-time PCR (RQ-PCR) (Guinn et al. 2007). The gene discussed is MIA2; the disease is acute myeloid leukemia.